Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Novel Agent First to Slow Disability in nrSPMS
COPENHAGEN, Denmark — A new investigational drug has become the first agent to slow disability in patients with nonrelapsing secondary progressive multiple sclerosis (nrSPMS). The Phase 3 HERCULES trial showed tolebrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor, delayed the…
English